FrancophonIA/ELRC3.0 huggingface dataset:
English: There was a small increase in plasma concentrations of capecitabine and one metabolite 5'-deoxy-5-fluorocytidine (5'-DFCR); there was no effect on the 3 major metabolites: 5'-deoxy-5-fluorouridine (5'-DFUR), 5-FU and α-fluoro-β-alanine (FBAL).
Slovenian: V plazmi so opazili majhno povečanje koncentracij kapecitabina in enega presnovka 5'-deoksi-5-fluorocitidina (5'-DFCR); na preostale tri glavne presnovke 5'-deoksi-5-fluorouridin (5'-DFUR) 5-FU in α-fluoro-β-alanin (FBAL) pa ni vplival.
English: • in combination with docetaxel (see section 5.1) for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.
Slovenian: • v kombinaciji z docetakselom (glejte poglavje 5.1) za zdravljenje bolnikov z lokalno napredovalo ali metastatsko obliko raka dojk po neuspešni citotoksični kemoterapiji.
English: -2nd appearance -3rd appearance -4th appearance
Slovenian: - 2. pojav - 3. pojav - 4. pojav dokončna prekinitev zdravljenja
English: • blood clots in the deep veins, high or low blood pressure, hot flushes, cold limbs (extremities),
Slovenian: • strdke krvi v globokih venah, visok ali nizek krvni tlak, vročinski oblivi, hladni udi (okončine),
English: • jaundice (yellowing of skin and eyes)
Slovenian: • zlatenica (rumenenje rože in oči),
English: These dose adjustment recommendations for renal impairment apply both to monotherapy and combination use (see also section “Elderly” below).
Slovenian: Priporočila za prilagajanje odmerkov pri ledvični okvari veljajo za samostojno in kombinirano zdravljenje (glejte tudi spodnji odstavek »Starejši bolniki«).
English: Patients were randomised to receive either FOLFIRI plus bevacizumab (Arm-A, n = 167) or XELIRI plus bevacizumab (Arm-B, n-166).
Slovenian: Bolnike so randomizirali, da so prejeli FOLFIRI in bevacizumab (skupina A, n = 167) ali XELIRI in bevacizumab (skupina B, n = 166).
English: • decrease in blood sodium, magnesium or calcium, increase in blood sugar
Slovenian: • zmanjšanje natrija, magnezija ali kalcija v krvi, povišanje sladkorja v krvi,
English: • Recent or concomitant treatment with brivudine (see section 4.4 and 4.5 for drug drug interaction),
Slovenian: • Nedavno ali sočasno zdravljenje z brivudinom (glede medsebojnega delovanja med zdravili glejte poglavji 4.4 in 4.5).
English: Grade 4 diarrhoea is an increase of ≥ 10 stools/day or grossly bloody diarrhoea or the need for parenteral support.
Slovenian: Driska stopnje 4 pomeni 10 ali več izpraznitev črevesa na dan ali močne krvave driske ali potrebo po parenteralni hidraciji.
English: • lumps under the skin (lipoma)
Slovenian: • bule pod kožo (lipome),
English: Table 5 lists ADRs associated with the use of capecitabine in combination with different chemotherapy regimens in multiple indications based on safety data from over 3,000 patients.
Slovenian: Preglednica 5 našteva neželene učinke, povezane z uporabo kapecitabina v kombinaciji z različnimi kemoterapijami pri več indikacijah, ki temeljijo na podatkih o varnosti, zbranih pri več kot 3.000 bolnikih.
English: • headache, sleepiness, dizziness, abnormal sensation in the skin (numbness or tingling sensation),
Slovenian: • glavobol, zaspanost, omotica, nenormalni občutek na koži (otrplost ali občutek ščemenja),
English: What Capecitabine medac is and what it is used for
Slovenian: Kaj je zdravilo Kapecitabin medac in za kaj ga uporabljamo
English: Some of these side effects are more common when capecitabine is used with other medicines for the treatment of cancer.
Slovenian: Nekateri od omenjenih neželenih učinkov so pogostejši, če kapecitabin jemljete skupaj z zdravili za zdravljenje raka.
English: You might get the following side effects if you take a lot more capecitabine than you should: feeling, or being sick, diarrhoea, inflammation or ulceration of the gut or mouth, pain or bleeding from the intestine or stomach, or bone marrow depression (reduction in certain kinds of blood cells).
Slovenian: Če ste vzeli veliko večji odmerek kapecitabina, kot bi smeli, vas lahko prizadenejo naslednji neželeni učinki: občutek bolezni ali bolnost, driska, vnetje ali razjede v črevesju ali ustih, bolečina ali krvavitev v črevesju ali želodcu ali depresija kostnega mozga (znižanje določenih vrst krvnih celic).
English: However, similar to other nucleoside analogues (i.e., 5-FU), capecitabine was clastogenic in human lymphocytes (in vitro) and a positive trend occurred in mouse bone marrow micronucleus tests (in vivo).
Slovenian: Podobno kakor drugi nukleozidni analogi, kot je 5-FU, je bil kapecitabin v človeških limfocitih klastogen (in vitro), mikronukleozni test (in vivo) v celicah kostnega mozga miši pa je imel pozitivno tendenco.
English: Capecitabine medac is not indicated in children and adolescents.
Slovenian: Zdravilo Kapecitabin medac ni namenjeno otrokom in mladostnikom.
English: Each pack contains 28, 30, 56, 60, 84, 112, or 120 film-coated tablets.
Slovenian: Vsako pakiranje vsebuje 28, 30, 56, 60, 84, 112 ali 120 filmsko obloženih tablet.
English: The ratio of 5-FU concentration in tumour to plasma was 21.4 (ranged from 3.9 to 59.9, n = 8) whereas the ratio in healthy tissues to plasma was 8.9 (ranged from 3.0 to 25.8, n = 8).
Slovenian: Razmerje koncentracij 5-FU v tumorjih v primerjavi s plazmo je bilo 21,4 (območje 3,9 do 59,9, n = 8), razmerje med zdravimi tkivi in plazmo pa 8,9 (območje 3,0 do 25,8, n = 8).
English: The pharmacokinetics of capecitabine have been evaluated over a dose range of 5023,514 mg/m²/day.
Slovenian: Farmakokinetiko kapecitabina so ocenjevali v odmerkih od 502 do 3.514 mg/m²/dan.
English: Cardiovascular toxicity (e.g. PR- and QT-interval prolongation) was detectable in cynomolgus monkeys after intravenous administration (100 mg/kg) but not after repeated oral dosing (1,379 mg/m²/day).
Slovenian: Toksično delovanje na srce in ožilje (podaljšanje intervalov PR in QT) so opazili pri opicah cynomolgus po intravenskem dajanju (100 mg/kg), po večkratnem peroralnem dajanju (1.379 mg/m²/dan) pa ne.
English: Table 4 lists ADRs associated with the use of capecitabine monotherapy based on a pooled analysis of safety data from three major studies including over 1,900 patients (studies M66001, SO14695, and SO14796).
Slovenian: Preglednica 4 našteva neželene učinke, povezane s samostojnim zdravljenjem s kapecitabinom, ki so jih zbrali z analizo podatkov o varnosti v treh glavnih kliničnih študijah pri več kot 1.900 bolnikih (študije M66001, SO14695 in SO14796).
English: At the beginning of a treatment cycle, if a treatment delay is indicated for either capecitabine or the other medicinal product(s), then administration of all therapy should be delayed until the requirements for restarting all medicinal products are met.
Slovenian: Kadar je na začetku cikla zdravljenja indicirano odloženo zdravljenje s kapecitabinom ali drugim zdravilom oz. drugimi zdravili, je treba odložiti zdravljenje z obema oz. vsemi, dokler niso vzpostavljeni pogoji za ponovno zdravljenje z vsemi zdravili.
English: The 5 year OS rate was 78 % for XELOX versus 74 % for 5-FU/LV.
Slovenian: Delež celokupnega petletnega preživetja je bil 78 % za shemo XELOX v primerjavi s 74 % za 5-FU/LV.
English: Patients treated with XELIRI experienced excessive gastrointestinal toxicity compared with FOLFIRI (diarrhoea 48 % and 14 % for XELIRI and FOLFIRI respectively).
Slovenian: Bolniki, zdravljeni s XELIRI, so imeli več gastrointestinalnih toksičnosti v primerjavi z bolniki, zdravljenimi s FOLFIRI (driska 48 % za XELIRI in 14 % za FOLFIRI).
English: If the other medicinal product(s) have to be discontinued permanently, capecitabine treatment can be resumed when the requirements for restarting capecitabine are met.
Slovenian: Če je treba zdravljenje z drugim zdravilom dokončno prekiniti, se lahko zdravljenje s kapecitabinom nadaljuje, ko so izpolnjeni pogoji za nadaljevanje zdravljenja s kapecitabinom.
English: • infections of the lungs or respiratory system (e.g. pneumonia or bronchitis)
Slovenian: • vnetje pljuč ali dihalnih poti (npr. pljučnico ali bronhitis),
English: The incidence of grade 3 or 4 adverse reactions in patients with moderate renal impairment (creatinine clearance 30 - 50 ml/min) is increased compared to the overall population (see sections 4.2 and 4.3).
Slovenian: Pogostnost pojavov neželenih učinkov stopnje 3 ali 4 pri bolnikih z zmerno ledvično okvaro (očistek kreatinina 30 do 50 ml/min) je v primerjavi s preostalo populacijo povečana (glejte poglavji 4.2 in 4.3).
English: Two examples are provided here: A person whose body weight is 64 kg and height is 1.64 m has a body surface area of 1.7 m² and should take 4 tablets of 500 mg and 1 tablet of 150 mg two times daily.
Slovenian: Navedena sta dva primera: oseba, ki tehta 64 kg in je visoka 1,64 m, ima telesno površino 1,7 m² in jemlje 4 tablete po 500 mg in 1 tableto po 150 mg dvakrat na dan.
English: There is some evidence that dexpanthenol is effective for HFS prophylaxis in patients treated with capecitabine.
Slovenian: Obstajajo dokazi, da je dekspantenol učinkovit pri preprečevanju sindroma roka-noga pri bolnikih, zdravljenih z zdravilom kapecitabinom.
English: Pack sizes: 28, 30, 56, 60, 84, 112 or 120 film-coated tablets.
Slovenian: Velikosti pakiranja: 28, 30, 56, 60, 84, 112 ali 120 filmsko obloženih tablet.
English: Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy should have their anticoagulant response (International Normalised Ratio [INR] or prothrombin time) monitored closely and the anticoagulant dose adjusted accordingly (see section 4.5).
Slovenian: Bolnikom, ki sočasno prejemajo kapecitabin in peroralni kumarinski antikoagulant, je treba skrbno spremljati antikoagulantni odziv (internacionalno normalizirano razmerje [INR] ali protrombinski čas) ter ustrezno prilagajati odmerek antikoagulanta (glejte poglavje 4.5).
English: • for the adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer (see section 5.1).
Slovenian: • za adjuvantno zdravljenje bolnikov po operaciji raka kolona stadija III (Dukes' C) (glejte poglavje 5.1).
English: • pain in the joints or in the limbs (extremities), chest or back
Slovenian: • bolečina v sklepih ali udih (okončinah), prsih ali hrbtu,
English: Dihydropyrimidine dehydrogenase (DPD) deficiency Rarely, unexpected, severe toxicity (e.g. stomatitis, diarrhoea, mucosal inflammation, neutropenia and neurotoxicity) associated with 5-fluorouracil (5-FU) has been attributed to a deficiency of DPD activity.
Slovenian: Redko, nepričakovano, hudo toksičnost (npr. stomatitis, drisko, vnetje sluznic, nevtropenijo in nevrotoksičnost), povezano s 5-fluorouracil (5-FU), pripisujemo pomanjkanju aktivnosti DPD.
English: If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.You must not take Capecitabine medac if you are pregnant or think you might be.
Slovenian: Če ste noseči ali dojite, menite, da bi lahko bili noseči, ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, preden vzamete to zdravilo.
English: For Aluminium-aluminium blisters:
Slovenian: Za aluminijeve-aluminijeve pretisne omote:
English: • for first-line treatment of advanced gastric cancer in combination with a platinum based regimen (see section 5.1).
Slovenian: • za prvo linijo zdravljenja napredovalega raka želodca v kombinaciji s shemo na osnovi platine (glejte poglavje 5.1).
English: If unscheduled laboratory assessments during a treatment cycle show that the neutrophil count drops below 1.0 x 109/L or that the platelet count drops below 75 x 109/L treatment with capecitabine should be interrupted.
Slovenian: Če laboratorijski izvid med ciklom zdravljenja pokaže, da se je število nevtrofilcev znižalo pod 1,0 x 109/l ali da se je število trombocitov znižalo pod 75 x 109/l,
English: A meta-analysis of six clinical trials (studies SO14695, SO14796, M66001, NO16966, NO16967, M17032) supports capecitabine replacing 5-FU in mono- and combination treatment in gastrointestinal cancer.
Slovenian: Meta-analiza šestih kliničnih preskušanj (študije SO14695, SO14796, M66001, NO16966, NO16967, M17032) podpira zamenjavo 5-FU s kapecitabinom pri zdravljenju raka prebavil, samostojno ali v kombinaciji z drugimi zdravili.
English: • cold sores or other herpes infections
Slovenian: • ustnični herpes ali druge okužbe s herpesom,
English: When capecitabine was used in combination with other medicinal products, elderly patients (≥ 65 years) experienced more grade 3 and grade 4 adverse drug reactions (ADRs), including those leading to discontinuation, compared to younger patients.
Slovenian: Kadar so kapecitabin uporabljali z drugimi zdravili, so imeli starejši bolniki (stari 65 let ali več) v primerjavi z mlajšimi več neželenih učinkov stopnje 3 in 4, vključno s tistimi, ki so povzročili ukinitev zdravila.
English: In human cancer xenograft models capecitabine demonstrated a synergistic effect in combination with docetaxel, which may be related to the upregulation of ThyPase by docetaxel.
Slovenian: V ksenografskih modelih raka pri ljudeh je imel kapecitabin v kombinaciji z docetakselom sinergistični učinek, kar je lahko povezano z uravnavanjem timidin fosforilaze zaradi docetaksela.
English: Titanium dioxide (E171)
Slovenian: Smukec Titanov dioksid (E 171)
English: • if you have diabetes,
Slovenian: • če imate sladkorno bolezen,
English: In patients with unrecognised DPD deficiency treated with capecitabine as well as in those patients who test negative for specific DPYD variations, life-threatening toxicities manifesting as acute overdose may occur (see section 4.9).
Slovenian: Pri bolnikih, pri katerih pomanjkanje DPD ni znano, kot tudi pri bolnikih z negativnim testom za specifične spremembe gena DPYD, ki jih zdravimo s kapecitabinom, se lahko pojavijo življensko ogrožujoče toksičnosti, ki se izrazijo kot akutno prekomerno odmerjanje (glejte poglavje 4.9).
English: The following factors were pre-specified in the statistical analysis plan for inclusion in the model: age, time from surgery to randomisation, gender, carcinoembryonic antigen (CEA) levels at baseline, lymph nodes at baseline, and country.
Slovenian: V načrtu statistične analize so bili za vključitev v model vnaprej določeni naslednji dejavniki: starost, čas od operacije do randomizacije, spol, izhodiščna vrednost karcinoembrionalnega antigena (CEA), izhodiščno stanje bezgavk, država.
English: • irregular heartbeat and palpitations (arrhythmias), chest pain and heart attack (infarction)
Slovenian: • neenakomerni srčni utrip in palpitacije (aritmije), bolečina v prsih in srčni napad (infarkt),
English: Other medicines and Capecitabine medac
Slovenian: Druga zdravila in Kapecitabin medac
English: What you need to know before you take Capecitabine medac
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Kapecitabin medac
English: Dihydropyrimidinase cleaves the pyrimidine ring to yield 5-fluoro-ureidopropionic acid (FUPA).
Slovenian: Dihidropirimidinaza cepi pirimidinski obroč, pri čemer nastane 5-fluoro-ureidopropionska kislina (FUPA).
English: The overall objective response rates in the all-randomised population (investigator assessment) were 25.7 % (capecitabine) vs. 16.7 % (Mayo regimen); p < 0.0002.
Slovenian: Celokupen odgovor v randomiziranih skupinah (raziskovalčeva ocena) je bil 25,7 % (kapecitabin) v primerjavi s 16,7 % (shema Mayo); p < 0,0002.
English: 28 film-coated tablets 30 film-coated tablets 56 film-coated tablets 60 film-coated tablets 84 film-coated tablets 112 film-coated tablets 120 film-coated tablets
Slovenian: 28 filmsko obloženih tablet 30 filmsko obloženih tablet 56 filmsko obloženih tablet 60 filmsko obloženih tablet 84 filmsko obloženih tablet 112 filmsko obloženih tablet 120 filmsko obloženih tablet
English: The parameters of capecitabine, 5'-DFCR and 5'-DFUR measured on days 1 and 14 were similar.
Slovenian: Parametri kapecitabina, 5'-deoksi-5-fluorocitidina (5'-DFCR) in 5'-deoksi-5-fluorouridina (5'-DFUR), ki so jih izmerili prvi in štirinajsti dan, so bili podobni.
English: In all studies combined, the following covariates were statistically significantly associated with an increased risk of developing HFS: increasing capecitabine starting dose (gram), decreasing cumulative capecitabine dose (0.1*kg), increasing relative dose intensity in the first six weeks, increasing duration of study treatment (weeks), increasing age (by 10 year increments), female gender, and good Eastern Cooperative Oncology Group (ECOG) performance status at baseline (0
Slovenian: Z večjim tveganjem za razvoj sindroma roka-noga so bile statistično značilno povezane naslednje sospremenljivke, povzete iz vseh študij: večji začetni odmerek kapecitabina (grami), manjši kumulativni odmerek kapecitabina (0,1*kg), večji odmerek v prvih šestih tednih, daljše zdravljenje (tedni), višja starost (v korakih po 10 let), ženski spol, dobro stanje zmogljivosti po ECOG (Eastern Cooperative Oncology Group) ob vključitvi (0 v primerjavi z ≥ 1).
English: Parameter: Progression-free survival
Slovenian: Parameter: Preživetje brez napredovanja bolezni
English: In patients with mild renal impairment (creatinine clearance 51 - 80 ml/min at baseline) no adjustment of the starting dose is recommended.
Slovenian: Bolnikom z blago ledvično okvaro (očistek kreatinina 51 do 80 ml/min na začetku zdravljenja) začetnega odmerka ni treba prilagajati.
English: In the EORTC study patients were randomised to receive either open label FOLFIRI (n = 41) or XELIRI (n = 44) with additional randomisation to either double-blind treatment with celecoxib or placebo.
Slovenian: V študiji EORTC so bolnike randomizirali, da so kot odprto zdravljenje prejeli FOLFIRI (n = 41) ali XELIRI (n = 44) in jih dodatno randomizirali v dvojno slepo zdravljenje s celekoksibom ali placebom.
English: • radiotherapy and certain medicines used to treat cancer (folinic acid, oxaliplatin, bevacizumab,
Slovenian: • radioterapiji in določenih zdravilih za zdravljenje raka (folinska kislina, oksaliplatin,
English: When capecitabine and cisplatin are used in combination, the use of vitamin B6 (pyridoxine) is not advised for symptomatic or secondary prophylactic treatment of HFS, because of published reports that it may decrease the efficacy of cisplatin.
Slovenian: Kadar kapecitabin in cisplatin uporabljamo v kombinaciji, ni priporočljiva uporaba vitamina B6 (piridoksina) za simptomatično ali sekundarno profilaktično zdravljenje sindroma roka-noga.
English: • inflammation leading to dysfunction or obstruction in bile secretion (cholestatic hepatitis)
Slovenian: • vnetje, ki vodi v nepravilno delovanje ali ovirano izločanja žolča (holestatski hepatitis),
English: A person whose body weight is 80 kg and height is 1.80 m has a body surface area of 2.00 m² and should take 5 tablets of 500 mg two times daily.
Slovenian: Oseba, ki tehta 80 kg in je visoka 1,80 m, ima telesno površino 2,00 m² in jemlje 5 tablet po 500 mg dvakrat na dan.
English: Capecitabine dose reduction decreases systemic exposure to 5-FU more than dose-proportionally, due to non--linear pharmacokinetics for the active metabolite.
Slovenian: Če zmanjšamo odmerek kapecitabina, se sistemska izpostavljenost 5-FU zaradi nelinearne farmakokinetike aktivnega presnovka zmanjša bolj kot sorazmerno z odmerkom.
English: Table 3 Capecitabine dose reduction schedule (3-weekly cycle or continuous treatment) Toxicity grades*
Slovenian: Shema za zmanjšanje odmerka pri zdravljenju s kapecitabinom (3-tedenski cikli ali neprekinjeno zdravljenje)
English: • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or fluorouracil,
Slovenian: • Preobčutljivost na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1
English: There is no data on capecitabine and impact on fertility.
Slovenian: Podatkov o vplivu kapecitabin na plodnost ni.
English: • medicines used to treat folic acid deficiency
Slovenian: • zdravil za zdravljenje pomanjkanja folne kisline.
English: According to immunohistochemical studies, ThyPase appears to be in large part localised in tumour stromal cells.
Slovenian: Imunohistokemične študije kažejo, da se timidin fosforilaza večinoma nahaja v tumorskih stromalnih celicah.
English: Median OS was 23.1 months for FOLFIRI, 17.6 months for mIFL (p = 0.09), and 18.9 months for XELIRI (p = 0.27).
Slovenian: Mediana celokupnega preživetja je bila 23,1 meseca za FOLFIRI, 17,6 meseca za mIFL (p = 0,09) in 18,9 meseca za XELIRI (p = 0,27).
English: • if you know that you do not have any activity of the enzyme dihydropyrimidine dehydrogenase (DPD),
Slovenian: • če veste, da nimate nobene aktivnosti encima dihidropirimidin dehidrogenaze (DPD),
English: Non-inferiority of the XELOX-containing arms compared with the FOLFOX-4-containing arms in the overall comparison was demonstrated in terms of progression-free survival (PFS) in the eligible patient population and the intent-to-treat population (see table 7).
Slovenian: Ne-inferiornost zdravljenja, ki vsebuje XELOX v primerjavi z zdravljenjem, ki vsebuje FOLFOX-4 v celokupni primerjavi, je bila dokazana glede na preživetje brez napredovanja bolezni v primerni populaciji bolnikov in populaciji bolnikov, ki so jo nameravali zdraviti (glejte preglednico 7).
English: Do not give Capecitabine medac to children and adolescents.
Slovenian: Otrokom in mladostnikom ne dajajte zdravila Kapecitabin medac.
English: If you are a male patient and your female partner could become pregnant, you should use effective contraception during treatment with Capecitabine medac and for 3 months after the last dose.
Slovenian: Če ste bolnik in bi vaša partnerka lahko zanosila, morate med zdravljenjem z zdravilom Kapecitabin medac in še 3 mesece po zadnjem odmerku zdravila uporabljati učinkovito kontracepcijo.
English: A clinically significant interaction between brivudine and fluoropyrimidines (e.g. capecitabine, 5-fluorouracil, tegafur), resulting from the inhibition of dihydropyrimidine dehydrogenase by brivudine, has been described.
Slovenian: Opisali so klinično pomembno medsebojno delovanje med brivudinom in fluoropirimidini (npr. kapecitabinom, 5-fluorouracilom in tegafurjem), ki je rezultat brivudinovega zaviranja dihidropirimidin dehidrogenaze.
English: • decreases in the number of white blood cells or red blood cells (seen in tests)
Slovenian: • zmanjšanje števila belih ali rdečih krvnih celic (razvidno iz preiskav),
English: Time to progressive disease was superior in the capecitabine + docetaxel combination arm (p < 0.0001).
Slovenian: Čas do napredovanja bolezni je bil v skupini, ki je jemala kapecitabin in docetaksel, daljši (p < 0,0001).
English: ThyPase activity was measured and found to be 4 times greater in primary colorectal tumour than in adjacent normal tissue.
Slovenian: Aktivnost timidin fosforilaze je štirikrat večja v primarnih kolorektalnih tumorjih kot v sosednjih zdravih tkivih.
English: • blood-thinning medicines (coumarin, warfarin)
Slovenian: • zdravil proti strjevanju krvi (kumarinov, varfarina),
English: Capecitabine is first metabolised by hepatic carboxylesterase to 5'-DFCR, which is then converted to 5'-DFUR by cytidine deaminase, principally located in the liver and tumour tissues.
Slovenian: Kapecitabin se najprej pretvori z jetrno karboksilesterazo v 5'-DFCR, ta pa se prek citidin deaminaze, ki se nahaja v jetrih in tumorskih tkivih, naprej pretvori v 5'-DFUR.
English: The MTD of capecitabine alone using the intermittent regimen is 3,000 mg/m² per day, whereas, when combined with radiotherapy for rectal cancer, the MTD of capecitabine is 2,000 mg/m² per day using either a continuous schedule or given daily Monday through Friday during a 6-week course of radiotherapy.
Slovenian: Največji prenosljivi odmerek kapecitabina samega pri intermitentnem dajanju je 3.000 mg/m² na dan, v kombinaciji z radioterapijo za rak danke pa je največji prenosljivi odmerek kapecitabina 2.000 mg/m² na dan z uporabo neprekinjene sheme ali dnevnim dajanjem od ponedeljka do petka med 6-tedensko radioterapijo.
English: 5-Fluorouracil 400 mg/m² intravenous bolus, followed by
Slovenian: 5-fluorouracil 400 mg/m² intravensko bolus, sledi 600 mg/m²